Isolation and characterisation of a human anti-idiotypic scFv used as a surrogate tumour antigen to elicit an anti-HER-2/neu humoral response in mice

HER-2/neu is a tumour antigen that is overexpressed in human breast tumours. Among the vaccine strategies developed to overcome immune tolerance to self-proteins, vaccination with anti-idiotypic (anti-Id) antibodies has been described as a promising approach for treatment of several malignant diseases. To develop an active immunotherapy for cancer patients positive for HER-2/neu, we investigated immunisation with human anti-Id single-chain fragments (scFv) mimicking the conformation of HER-2/neu protein to induce a humoral response in mice. We selected by phage display two human anti-Id scFv (Ab2β) directed against trastuzumab F(ab′)2 fragments (Ab1), a humanised anti-HER-2/neu monoclonal antibody. Using competitive ELISA and Biacore biosensor analysis, we showed that anti-Id scFv 40 and scFv 69 could inhibit HER-2/neu binding to trastuzumab. Following vaccination of BALB/c mice with the soluble or phage-displayed scFv, Ab3 polyclonal antibodies, and among them Ab1′ antibodies able to bind HER-2/neu, were detected in the sera of the immunised mice. These results demonstrate that the human anti-Id scFv could act as a surrogate antigen for HER-2/neu. The present study strongly suggests that the novel 30 kDa human mini-antibody could be used as an anti-idiotype-based vaccine formulation to induce an effective humoral response in patients bearing HER-2/neu-positive tumours.

[1]  P. Musiani,et al.  Inhibition of mammary carcinogenesis by systemic interleukin 12 or p185neu DNA vaccination in Her-2/neu transgenic BALB/c mice. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  C. Dean,et al.  Vaccination with syngeneic monoclonal anti-idiotype protects against a tumour challenge. , 1987, Immunology.

[3]  I. Tomlinson,et al.  Selection of large diversities of antiidiotypic antibody fragments by phage display. , 2002, Journal of molecular biology.

[4]  R. Kennedy,et al.  Suppression of in vivo tumor formation induced by simian virus 40- transformed cells in mice receiving antiidiotypic antibodies , 1985, The Journal of experimental medicine.

[5]  J. Baselga,et al.  Mechanism of action of anti-HER2 monoclonal antibodies. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  Cori Bargmann,et al.  The neu oncogene encodes an epidermal growth factor receptor-related protein , 1986, Nature.

[7]  M. Provinciali,et al.  Autoantibody to p185erbB2/neu oncoprotein by vaccination with xenogenic DNA , 1997, Cancer Immunology, Immunotherapy.

[8]  K. Foon,et al.  Antigen mimicry by an anti-idiotypic antibody single chain variable fragment. , 1998, Molecular immunology.

[9]  P. Seeburg,et al.  Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. , 1985, Science.

[10]  J. Wharton,et al.  Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines , 1995, The Journal of experimental medicine.

[11]  M. Cheever,et al.  Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  K. Foon,et al.  Murine dendritic cells pulsed with an anti-idiotype antibody induce antigen-specific protective antitumor immunity. , 2003, Cancer research.

[13]  Jerne Nk.  Towards a network theory of the immune system. , 1974 .

[14]  R. Bast,et al.  Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. , 1990, Cancer research.

[15]  R. Begent,et al.  Purification of bacterially expressed single chain Fv antibodies for clinical applications using metal chelate chromatography. , 1995, Journal of immunological methods.

[16]  G. Mancuso,et al.  Neonatal mouse immunity against group B streptococcal infection by maternal vaccination with recombinant anti-idiotypes , 1998, Nature Medicine.

[17]  P. Triozzi,et al.  Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine. , 2000, Cancer research.

[18]  K. Foon,et al.  Murine monoclonal anti‐idiotypic antibody as a surrogate antigen for human Her‐2/neu , 2001, International journal of cancer.

[19]  N K Jerne,et al.  Towards a network theory of the immune system. , 1973, Annales d'immunologie.

[20]  N. Robert,et al.  Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  A. Ullrich,et al.  Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic , 1991, Journal of Clinical Immunology.

[22]  J. Gralow,et al.  Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein. , 1996, Journal of immunology.

[23]  T. Eberlein,et al.  Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[24]  K. Hellström,et al.  Immunotherapy of murine sarcomas with auto-anti-idiotypic monoclonal antibodies which bind to tumor-specific T cells. , 1987, Journal of immunology.

[25]  E. Sercarz,et al.  Induction of anti-self-immunity to cure cancer , 1995, Cell.

[26]  J. Ledbetter,et al.  Activity of a single-chain immunotoxin that selectively kills lymphoma and other B-lineage cells expressing the CD40 antigen. , 1995, Cancer research.

[27]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[28]  Wei Chen,et al.  Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. , 1994, Cancer research.

[29]  M. Piechocki,et al.  Vaccination with Cytoplasmic ErbB-2 DNA Protects Mice from Mammary Tumor Growth Without Anti-ErbB-2 Antibody1 , 2001, The Journal of Immunology.

[30]  D. Neri,et al.  The use of phage display for the development of tumour targeting agents. , 2000, Advanced drug delivery reviews.

[31]  T. Kageshita,et al.  Active specific immunotherapy in patients with melanoma. A clinical trial with mouse antiidiotypic monoclonal antibodies elicited with syngeneic anti-high-molecular-weight-melanoma-associated antigen monoclonal antibodies. , 1990, The Journal of clinical investigation.

[32]  A. Pini,et al.  Design and Use of a Phage Display Library , 1998, The Journal of Biological Chemistry.

[33]  K. Foon,et al.  Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  B. Seon,et al.  Idiotype vaccines against human T cell leukemia. II. Generation and characterization of a monoclonal idiotype cascade (Ab1, Ab2, and Ab3). , 1988, Journal of immunology.

[35]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[36]  G. Winter,et al.  Making antibodies by phage display technology. , 1994, Annual review of immunology.

[37]  K. Foon,et al.  Anti-idiotype monoclonal antibodies as vaccines for human cancer. , 1991, International reviews of immunology.

[38]  L. Demers,et al.  Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  Cheever,et al.  Human HER‐2/neu protein immunization circumvents tolerance to rat neu: a vaccine strategy for ‘self’ tumour antigens , 1998, Immunology.

[40]  K. Foon,et al.  Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  D Tripathy,et al.  Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  S. Ménard,et al.  Prognostic significance of her‐2/neu expression in breast cancer and its relationship to other prognostic factors , 1991, International journal of cancer.

[43]  R. Levy,et al.  Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. , 1992, The New England journal of medicine.

[44]  F. Felici,et al.  Immunization with phage-displayed mimotopes. , 1996, Methods in enzymology.